Sonoma Pharmaceuticals, Inc.
SNOA Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$1.12
KIRA · Stoqly’s AI analyst, in plain words
- Sonoma Pharmaceuticals, Inc. had $19.5M of revenue in fiscal 2026, up 36.7% on the year before. Over five years, revenue changed +0.9% a year on average.
- Its operating margin was −12.6%, up 13.4 pts: of every 100 in sales, about −13 is left after running the business.
- Sonoma Pharmaceuticals, Inc. lost $3.2M in fiscal 2026.
- Free cash flow was −$4.1M in fiscal 2026, −21.1% of revenue.
- Sonoma Pharmaceuticals, Inc. has $2.2M more cash than debt.
Market cap
$4.3M
P/E
—
Revenue
$19.5M
Net income
−$3.2M
Free cash flow
−$4.1M
Operating margin
−12.6%
Sonoma Pharmaceuticals, Inc. in 30 seconds · fiscal 2026
Are sales growing?
+36.7%
Yes. Sales grew 36.7% last year.
Does it make a profit?
−16.3%
No. It lost money last year.
Does profit turn into cash?
−21.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Sonoma Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · Jun 16, 2026
- Legal name
- Sonoma Pharmaceuticals, Inc.
- CIK
- 0001367083
Sonoma Pharmaceuticals, Inc. · SNOA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M |
| Revenue growth | −32.2% | 5.1% | −4.0% | 12.2% | 36.7% |
| Net interest income | −$0.0M | $0.0M | — | — | — |
| Gross margin | 31.6% | 33.7% | 37.3% | 38.2% | 38.0% |
| Operating margin | −46.6% | −34.4% | −36.9% | −26.0% | −12.6% |
| Net income | −$5.1M | −$5.2M | −$4.8M | −$3.5M | −$3.2M |
| Net margin | −40.3% | −38.8% | −38.0% | −24.2% | −16.3% |
| Diluted EPS | −$1.92 | −$1.52 | −$10.63 | −$2.79 | −$1.89 |
| Cash | |||||
| Cash from operations | −$4.2M | −$6.2M | −$2.4M | −$0.1M | −$3.9M |
| Capital expenditure | $0.1M | $0.3M | $0.0M | $0.1M | $0.2M |
| Free cash flow | −$4.4M | −$6.4M | −$2.4M | −$0.2M | −$4.1M |
| FCF margin | −34.7% | −48.4% | −18.8% | −1.2% | −21.1% |
| Share count change | −99.9% | 125,603.7% | −86.6% | 172.7% | 35.7% |
| Debt and strength | |||||
| Cash and short-term investments | $7.4M | $3.8M | $3.1M | $5.4M | $2.4M |
| Debt incl. finance leases | $0.0M | $0.4M | $0.3M | $0.2M | $0.2M |
| Shareholders' equity | $8.7M | $8.0M | $6.1M | $4.4M | $3.1M |
| Current ratio | 2.8x | 3.7x | 3.4x | 3.1x | 2.5x |
| Returns and quality | |||||
| Return on capital | −357.5% | −78.7% | −111.5% | — | −211.8% |
| Return on equity | −72.3% | −61.8% | −68.5% | −65.5% | −84.6% |
| Return on tangible equity | −58.5% | −64.6% | −78.8% | −78.4% | −102.6% |
| Piotroski F-score | 3 | 3 | 5 | 5 | 3 |
| Altman Z'' | −29.4 | −34.9 | −40.4 | −44.3 | −44.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sonoma Pharmaceuticals, Inc. · SNOA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.12 a share, the company is worth $4.3M.
Source: SEC EDGAR XBRL filings (CIK 0001367083). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.